MULTIPLE MYELOMA REFRACTORY

This study is testing whether a new type of cancer treatment called universal CAR-T cells is safe and effective for adults with multiple myeloma that has returned or stopped responding to other treatments. The treatment uses specially engineered immune cells from donors (not the …

This study aims to find the best level of protective antibodies to give patients with hard-to-treat multiple myeloma who are receiving a new type of immunotherapy. The new treatment can weaken the immune system, raising the risk of serious infections. Researchers are comparing wh…

This study is testing a new type of treatment called anti-BCMA CAR-T cell therapy for adults with multiple myeloma that has come back or stopped responding to other treatments. Doctors will take a patient's own immune cells, modify them in a lab to better fight the cancer, and th…

This study is testing whether adding a new drug called inobrodib to two standard medications can help control multiple myeloma that has come back and no longer responds to available therapies. It will involve about 100 adults whose cancer has progressed despite trying several oth…

This study is testing whether adding the drug selinexor to a newer type of immunotherapy (called a bispecific antibody) is safe and more effective for people with multiple myeloma that has come back or stopped responding to other treatments. It will enroll 27 patients who have al…

This study is testing two different drug combinations for people with multiple myeloma that has stopped responding to multiple standard treatments. Researchers want to see if adding a new drug called selinexor to existing medications can help control the cancer. The trial is enro…

This study is testing if adding early palliative (comfort) care to standard cancer treatment improves well-being for patients with multiple myeloma or aggressive lymphoma. It will involve 144 patients, and some of their caregivers, who will be randomly assigned to receive either …